CoChat

Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary prevention

Open access
Perreault, S., Blais, L., Lamarre, D., Dragomir, A., Berbiche, D., Lalonde, L., Laurier, C., St‐Maurice, F., Collin, J. · 2005 · British Journal of Clinical Pharmacology
Cited by 146

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Aims: Statins have been shown to significantly reduce morbidity and mortality in patients with coronary artery disease (CAD), and also in patients with dyslipidaemia when statins are taken regularly. Middle‐aged patients have the highest level of forecasting benefit and little is known about persistence rate of these therapies in a real‐life setting. The objective was to evaluate the persistence rate of middle‐aged patients initiating a statin therapy and its relation with several determinants for primary and secondary prevention. Methods: A cohort was reconstructed using the RAMQ databases. All patients aged 50–64 years‐old who received at least one statin prescription between 1 January, 1998 and 31 December, 2000 for a new intention of treatment for dyslipidaemia were included in the cohort and followed up until 30 June, 2001. The date of the first prescription of statin was defined as the index date. There were 4316 patients in the secondary prevention (CAD diagnosis) and 13 642 patients in primary prevention cohort. The cumulative persistence rate was estimated using Kaplan‐Meier, and Cox regression models were used to estimate the hazard ratio of ceasing statins. Results: We found that persistence with statins had fallen to 71% after 6 months of treatment, and had declined to 45% after 3 years in the secondary prevention cohort; the corresponding figures were 65% and 35% in the primary prevention cohort. Our results suggest that patients with dyslipidaemia in primary prevention compared with those in secondary prevention (HR: 1.18; 1.11–1.25) are less likely to be persistent. Patients with other cardiovascular risk factors such as age (HR: 0.99; 0.98–0.99), diabetes (HR: 0.84; 0.79–0.90), hypertension (HR: 0.76; 0.72–0.80) were most likely to be persistent with statins. We observed lower persistence in patients who have used the greatest number of pharmacies and prescribing physicians. Conclusion: This analysis indicates that barriers to persistence occur early in the therapeutic course. Overall persistence with statins is low, and particularly among patients with few other cardiovascular risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2005.02355.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 146

Metadata

Authors
Perreault, S., Blais, L., Lamarre, D., Dragomir, A., Berbiche, D., Lalonde, L., Laurier, C., St‐Maurice, F., & Collin, J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2005-03-02
Volume
59
Issue
5
Pages
564-573
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2079134517
Cited by
146
References
16
FWCI
5.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary prevention. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02355.x
The paper
Perreault, S., Blais, L., Lamarre, D., Dragomir, A., Berbiche, D., Lalonde, L., Laurier, C., St‐Maurice, F., & Collin, J. (2005). Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary prevention. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02355.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.